CIO - Centro de Inmuno-Oncología de Occidente (Site 0592)

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Metastatic breast cancer

Running trials

• Recruiting

  A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  NCT06312176· Phase 3· Merck Sharp & Dohme LLC· Source

  Contact: Toll Free Number